R.F. Roscigno

491 total citations
14 papers, 359 citations indexed

About

R.F. Roscigno is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, R.F. Roscigno has authored 14 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 4 papers in Physiology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in R.F. Roscigno's work include Pulmonary Hypertension Research and Treatments (10 papers), Asthma and respiratory diseases (3 papers) and Inhalation and Respiratory Drug Delivery (2 papers). R.F. Roscigno is often cited by papers focused on Pulmonary Hypertension Research and Treatments (10 papers), Asthma and respiratory diseases (3 papers) and Inhalation and Respiratory Drug Delivery (2 papers). R.F. Roscigno collaborates with scholars based in United States, United Kingdom and France. R.F. Roscigno's co-authors include Carl Arneson, Thomas L. Hunt, Vallerie V. McLaughlin, Michael S. Wade, Lewis J. Rubin, Allen A. Lai, Stuart Rich, Robyn J. Barst, Adaani Frost and Victor F. Tapson and has published in prestigious journals such as The Journal of Heart and Lung Transplantation, The Journal of Clinical Pharmacology and Journal of Cardiovascular Pharmacology.

In The Last Decade

R.F. Roscigno

13 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.F. Roscigno United States 8 313 216 67 40 34 14 359
Michela Efficace Switzerland 5 440 1.4× 368 1.7× 66 1.0× 39 1.0× 34 1.0× 11 487
Martha Kingman United States 9 262 0.8× 194 0.9× 41 0.6× 26 0.7× 21 0.6× 21 305
Jennie Newman United States 10 353 1.1× 231 1.1× 36 0.5× 60 1.5× 17 0.5× 14 432
J.-L. Jagot France 4 354 1.1× 216 1.0× 79 1.2× 29 0.7× 41 1.2× 8 374
Sylvia Nikkho Germany 14 559 1.8× 358 1.7× 93 1.4× 47 1.2× 65 1.9× 33 622
T. V. Martynyuk Russia 11 337 1.1× 267 1.2× 30 0.4× 12 0.3× 13 0.4× 134 446
Hans P. Gurtner United States 4 177 0.6× 171 0.8× 66 1.0× 25 0.6× 12 0.4× 5 277
K. Akaya Smith United States 8 221 0.7× 138 0.6× 26 0.4× 28 0.7× 13 0.4× 14 256
Coralie Shaw United States 11 290 0.9× 59 0.3× 18 0.3× 87 2.2× 13 0.4× 16 420

Countries citing papers authored by R.F. Roscigno

Since Specialization
Citations

This map shows the geographic impact of R.F. Roscigno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.F. Roscigno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.F. Roscigno more than expected).

Fields of papers citing papers by R.F. Roscigno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.F. Roscigno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.F. Roscigno. The network helps show where R.F. Roscigno may publish in the future.

Co-authorship network of co-authors of R.F. Roscigno

This figure shows the co-authorship network connecting the top 25 collaborators of R.F. Roscigno. A scholar is included among the top collaborators of R.F. Roscigno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.F. Roscigno. R.F. Roscigno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Frantz, Robert P., J.W. McConnell, R.F. Roscigno, et al.. (2021). A Phase 1b, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension. A3602–A3602. 2 indexed citations
3.
Roscigno, R.F., et al.. (2021). Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. Vascular Pharmacology. 138. 106840–106840. 8 indexed citations
4.
Frantz, Robert P., Raymond L. Benza, Richard N. Channick, et al.. (2021). TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation. 11(4). 1–7. 37 indexed citations
5.
Roscigno, R.F., et al.. (2020). Pharmacokinetics and tolerability of LIQ861, a novel dry‐powder formulation of treprostinil. Pulmonary Circulation. 10(4). 1–9. 12 indexed citations
6.
7.
Feldman, Jeremy P., et al.. (2020). INSPIRE: Final Results from a Phase 3, Open-Label, Pivotal Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. 39(4). S17–S18. 2 indexed citations
8.
9.
10.
Lovich, Mark A., Matthew J. Pezone, Michael R. Murray, et al.. (2015). Inhaled Nitric Oxide Augments Left Ventricular Assist Device Capacity by Ameliorating Secondary Right Ventricular Failure. ASAIO Journal. 61(4). 379–385. 17 indexed citations
11.
Lovich, Mark A., David H. Fine, L.G. Gamero, et al.. (2014). Generation of purified nitric oxide from liquid N2O4 for the treatment of pulmonary hypertension in hypoxemic swine. Nitric Oxide. 37. 66–72. 17 indexed citations
12.
Wade, Michael S., et al.. (2004). Pharmacokinetics of Treprostinil Sodium Administered by 28‐Day Chronic Continuous Subcutaneous Infusion. The Journal of Clinical Pharmacology. 44(5). 503–509. 35 indexed citations
13.
McLaughlin, Vallerie V., Seán Gaine, Robyn J. Barst, et al.. (2003). Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology. 41(2). 293–299. 176 indexed citations
14.
Wade, Michael S., et al.. (2003). Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. The Journal of Clinical Pharmacology. 44(1). 83–88. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michela Efficace Breakdown of academic impact, for papers by Martha Kingman Breakdown of academic impact, for papers by Jennie Newman Breakdown of academic impact, for papers by J.-L. Jagot Breakdown of academic impact, for papers by Sylvia Nikkho Breakdown of academic impact, for papers by T. V. Martynyuk Breakdown of academic impact, for papers by Hans P. Gurtner Breakdown of academic impact, for papers by K. Akaya Smith Breakdown of academic impact, for papers by Coralie Shaw
Rankless by CCL
2026